PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 256 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $685,974 | -56.4% | 22,359 | -43.1% | 0.00% | 0.0% |
| Q2 2023 | $1,575,031 | -3.1% | 39,307 | -1.3% | 0.00% | 0.0% |
| Q1 2023 | $1,625,013 | +5.6% | 39,819 | -0.1% | 0.00% | 0.0% |
| Q4 2022 | $1,538,917 | -18.7% | 39,858 | +12.0% | 0.00% | -50.0% |
| Q3 2022 | $1,893,000 | -16.9% | 35,597 | -8.9% | 0.00% | 0.0% |
| Q2 2022 | $2,279,000 | -15.4% | 39,086 | +10.7% | 0.00% | 0.0% |
| Q1 2022 | $2,694,000 | +29.8% | 35,299 | +2.3% | 0.00% | 0.0% |
| Q4 2021 | $2,076,000 | +20.7% | 34,508 | +12.4% | 0.00% | 0.0% |
| Q3 2021 | $1,720,000 | -1.5% | 30,708 | +6.7% | 0.00% | 0.0% |
| Q2 2021 | $1,746,000 | -14.7% | 28,779 | -1.5% | 0.00% | 0.0% |
| Q1 2021 | $2,047,000 | +605.9% | 29,203 | +503.6% | 0.00% | – |
| Q4 2020 | $290,000 | -33.8% | 4,838 | -33.6% | 0.00% | -100.0% |
| Q3 2020 | $438,000 | +74.5% | 7,282 | +52.2% | 0.00% | – |
| Q2 2020 | $251,000 | +1.6% | 4,786 | -34.9% | 0.00% | – |
| Q1 2020 | $247,000 | -38.1% | 7,355 | -16.5% | 0.00% | -100.0% |
| Q4 2019 | $399,000 | +54.1% | 8,813 | +29.4% | 0.00% | – |
| Q3 2019 | $259,000 | -27.2% | 6,813 | -16.8% | 0.00% | -100.0% |
| Q2 2019 | $356,000 | -52.9% | 8,188 | -58.8% | 0.00% | 0.0% |
| Q1 2019 | $756,000 | -24.1% | 19,863 | -14.2% | 0.00% | -50.0% |
| Q4 2018 | $996,000 | +43.7% | 23,161 | +7.2% | 0.00% | +100.0% |
| Q2 2018 | $693,000 | +25.3% | 21,611 | +21.7% | 0.00% | 0.0% |
| Q1 2018 | $553,000 | -82.4% | 17,761 | -74.1% | 0.00% | -83.3% |
| Q4 2017 | $3,136,000 | +25.6% | 68,691 | +3.3% | 0.01% | +20.0% |
| Q3 2017 | $2,496,000 | +110.6% | 66,475 | +167.6% | 0.01% | +66.7% |
| Q2 2017 | $1,185,000 | +146.4% | 24,845 | +135.8% | 0.00% | +200.0% |
| Q1 2017 | $481,000 | +124.8% | 10,538 | +59.0% | 0.00% | 0.0% |
| Q4 2016 | $214,000 | -60.7% | 6,628 | -58.3% | 0.00% | 0.0% |
| Q3 2016 | $544,000 | +15.0% | 15,907 | +13.4% | 0.00% | 0.0% |
| Q2 2016 | $473,000 | -26.2% | 14,025 | +16.0% | 0.00% | -50.0% |
| Q1 2016 | $641,000 | -84.6% | 12,090 | -79.4% | 0.00% | -87.5% |
| Q2 2015 | $4,155,000 | -50.6% | 58,755 | -38.0% | 0.02% | -56.8% |
| Q1 2015 | $8,417,000 | +6.7% | 94,737 | +6.5% | 0.04% | -5.1% |
| Q4 2014 | $7,889,000 | -11.7% | 88,982 | -3.5% | 0.04% | -23.5% |
| Q3 2014 | $8,935,000 | -4.8% | 92,187 | -9.8% | 0.05% | -12.1% |
| Q2 2014 | $9,385,000 | +18.1% | 102,167 | -10.0% | 0.06% | +7.4% |
| Q1 2014 | $7,949,000 | +35.4% | 113,577 | +11.2% | 0.05% | +22.7% |
| Q4 2013 | $5,870,000 | +70.8% | 102,100 | +42.8% | 0.04% | +46.7% |
| Q3 2013 | $3,437,000 | +21.5% | 71,500 | -26.7% | 0.03% | +11.1% |
| Q2 2013 | $2,828,000 | – | 97,500 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |